KYMR
Kymera Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$118.18
+0.76%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 105.0M | 39.2M | 47.1M | 78.6M | 46.8M |
| Cost of Revenue | (2.1M) | — | — | — | — |
| Gross Profit | 107.1M | 39.2M | 47.1M | 78.6M | 46.8M |
| Operating Expenses | |||||
| R&D Expense | 375.6M | 316.6M | 240.2M | 189.1M | 164.2M |
| SG&A Expense | 75.8M | 68.2M | 63.5M | 55.0M | 43.8M |
| General & Admin Expense | 75.8M | 68.2M | 63.5M | 55.0M | 43.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 5.9M | 3.8M | 4.9M | — | — |
| Total Operating Expenses | 457.3M | 388.6M | 308.7M | 244.1M | 208.1M |
| Cost and Expenses | 455.2M | 388.6M | 308.7M | 244.1M | 208.1M |
| Operating Income (EBIT) | (350.2M) | (349.4M) | (261.6M) | (165.5M) | (161.3M) |
| Non-Operating | |||||
| Interest Income | 50.5M | 38.0M | 38.0M | 18.8M | 6.6M |
| Interest Expense | 211.0K | 249.0K | 249.0K | 196.0K | 176.0K |
| Net Interest Income | 50.3M | 37.8M | 37.8M | 18.6M | 6.4M |
| Other Non-Op Income/Expense | 50.3M | 37.8M | 37.8M | 18.6M | 6.4M |
| Non-Operating Income (excl Interest) | (50.5M) | (38.0M) | (38.0M) | (18.8M) | (6.6M) |
| EBT (Pre-Tax Income) | (299.9M) | (311.6M) | (223.9M) | (147.0M) | (154.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (299.6M) | (311.4M) | (223.9M) | (147.0M) | (154.8M) |
| Earnings from Cont. Ops | (299.9M) | (311.6M) | (223.9M) | (147.0M) | (154.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (299.6M) | (311.4M) | (223.9M) | (147.0M) | (154.8M) |
| Per Share | |||||
| Basic EPS | ($3.25) | ($3.69) | ($2.98) | ($2.52) | ($2.87) |
| Diluted EPS | ($3.25) | ($3.69) | ($2.98) | ($2.52) | ($2.87) |
| Revenue Per Share | $1.07 | $0.46 | $0.63 | $1.35 | $0.87 |
| Shares | |||||
| Basic Shares Outstanding | 98.2M | 84.4M | 75.0M | 58.4M | 53.9M |
| Diluted Shares Outstanding | 98.2M | 84.4M | 75.0M | 58.4M | 53.9M |
| Profitability Metrics | |||||
| EBITDA | (292.8M) | (303.1M) | (216.2M) | (143.2M) | (151.7M) |
| D&A | 6.9M | 8.3M | 7.4M | 3.6M | 3.0M |
| EBIT | (299.7M) | (311.4M) | (223.6M) | (146.8M) | (154.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026